This study is testing a new medication called HMB-002 for people with Von Willebrand Disease (VWD), including Types 1, 2, and 3. The main goal is to see how safe HMB-002 is and how well your body tolerates it. Researchers will also look at how the drug moves through your body (pharmacokinetics) and what effects it has (pharmacodynamics). You might receive HMB-002 alone or with another treatment called factor concentrate. To join, you need to be between 16 and 69 years old, weigh 50 to 120 kg, and have a confirmed diagnosis of VWD. The study is currently evaluating safety and dosage.

Study design

This is a Phase 1/2, open-label study with three parts, designed to test different doses and how HMB-002 is given. It plans to enroll 108 participants.

What's involved

Depending on the part of the study, your participation could last approximately 12, 17, or 21 weeks. You will receive HMB-002 as an injection under the skin.

Compensation

Not stated in the trial record.

Follow-up

Your safety will be monitored for up to 113 days after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.